Free Trial
→ June 12: $100 Turns Into $100,000? (From Brownstone Research) (Ad)tc pixel Free SMFL Stock Alerts

Smart for Life (SMFL) Competitors

Smart for Life logo
$0.0010 0.00 (0.00%)
As of 06/9/2026
Compare

SMFL vs. SCPS, VAXX, ARDS, TRVN, and NAVB

Should you buy Smart for Life stock or one of its competitors? MarketBeat compares Smart for Life with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Smart for Life include Scopus BioPharma (SCPS), Vaxxinity (VAXX), Aridis Pharmaceuticals (ARDS), Trevena (TRVN), and Navidea Biopharmaceuticals (NAVB). These companies are all part of the "pharmaceutical products" industry.

How does Smart for Life compare to Scopus BioPharma?

Smart for Life (NASDAQ:SMFL) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

Scopus BioPharma has lower revenue, but higher earnings than Smart for Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Scopus BioPharma N/A N/A N/A

28.4% of Smart for Life shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Smart for Life has a beta of 14.81, indicating that its share price is 1,381% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market.

In the previous week, Scopus BioPharma had 1 more articles in the media than Smart for Life. MarketBeat recorded 1 mentions for Scopus BioPharma and 0 mentions for Smart for Life. Smart for Life's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Scopus BioPharma Neutral

Summary

Smart for Life beats Scopus BioPharma on 4 of the 6 factors compared between the two stocks.

How does Smart for Life compare to Vaxxinity?

Smart for Life (NASDAQ:SMFL) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

28.4% of Smart for Life shares are owned by institutional investors. Comparatively, 82.9% of Vaxxinity shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by insiders. Comparatively, 64.1% of Vaxxinity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Vaxxinity Neutral

Smart for Life has a beta of 14.81, meaning that its share price is 1,381% more volatile than the broader market. Comparatively, Vaxxinity has a beta of -79.33, meaning that its share price is 8,033% less volatile than the broader market.

Smart for Life has higher revenue and earnings than Vaxxinity. Vaxxinity is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
VaxxinityN/AN/A-$56.93M-$0.45N/A

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Vaxxinity N/A N/A N/A

Summary

Smart for Life beats Vaxxinity on 4 of the 7 factors compared between the two stocks.

How does Smart for Life compare to Aridis Pharmaceuticals?

Smart for Life (NASDAQ:SMFL) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Aridis Pharmaceuticals N/A N/A N/A

Smart for Life has higher revenue and earnings than Aridis Pharmaceuticals. Smart for Life is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.00

28.4% of Smart for Life shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Aridis Pharmaceuticals had 1 more articles in the media than Smart for Life. MarketBeat recorded 1 mentions for Aridis Pharmaceuticals and 0 mentions for Smart for Life. Smart for Life's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Aridis Pharmaceuticals Neutral

Smart for Life has a beta of 14.81, suggesting that its share price is 1,381% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 44.97, suggesting that its share price is 4,397% more volatile than the broader market.

Summary

Smart for Life and Aridis Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

How does Smart for Life compare to Trevena?

Trevena (NASDAQ:TRVN) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Smart for Life N/A N/A N/A

13.6% of Trevena shares are held by institutional investors. Comparatively, 28.4% of Smart for Life shares are held by institutional investors. 2.7% of Trevena shares are held by company insiders. Comparatively, 31.7% of Smart for Life shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Smart for Life has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.02-$40.29M-$47.04N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

In the previous week, Trevena had 1 more articles in the media than Smart for Life. MarketBeat recorded 1 mentions for Trevena and 0 mentions for Smart for Life. Trevena's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Trevena Neutral
Smart for Life Neutral

Trevena has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Smart for Life has a beta of 14.81, suggesting that its share price is 1,381% more volatile than the broader market.

Summary

Smart for Life beats Trevena on 8 of the 10 factors compared between the two stocks.

How does Smart for Life compare to Navidea Biopharmaceuticals?

Smart for Life (NASDAQ:SMFL) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

Navidea Biopharmaceuticals has lower revenue, but higher earnings than Smart for Life. Smart for Life is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Smart for Life has a beta of 14.81, indicating that its stock price is 1,381% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

28.4% of Smart for Life shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 31.7% of Smart for Life shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Navidea Biopharmaceuticals Neutral

Summary

Smart for Life beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

Get Smart for Life News Delivered to You Automatically

Sign up to receive the latest news and ratings for SMFL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMFL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SMFL vs. The Competition

Export
MetricSmart for LifeMedicinals & botanicals IndustryMedical SectorNASDAQ Exchange
Market Cap$7K$4.16B$6.49B$11.95B
Dividend YieldN/AN/A2.67%5.61%
P/E Ratio0.009.2024.4023.63
Price / Sales0.001.96478.4384.19
Price / CashN/A7.5343.0554.72
Price / Book0.001.5810.306.70
Net Income-$22.68M$10.91M$3.56B$337.26M
7 Day PerformanceN/A-5.10%-3.01%-2.46%
1 Month PerformanceN/A-6.61%-0.39%0.31%
1 Year PerformanceN/A30.70%20.03%23.15%

Smart for Life Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SMFL
Smart for Life
N/A$0.00
flat		N/A-88.4%$7K$11.11MN/A110
SCPS
Scopus BioPharma
N/A$0.00
flat		N/A+33.3%$25KN/AN/A9
VAXX
Vaxxinity
N/A$0.00
+100.0%		N/A+50.0%$25KN/AN/A90
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/A+100.0%$11KN/A0.0030
TRVN
Trevena
N/A$0.01
+1,010.0%		N/A-98.9%$11K$443KN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SMFL) was last updated on 6/11/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel